Case todayOn watchEarly warning: revenue decline (trailing 12 months) · Oct 28, 2026The case · holding · Oct 17, 2026Own AMWL if large healthcare buyers keep paying for a dedicated digital-care platform while management turns a still-lossmaking revenue base into self-funding cash flow.4 conditions2 strengthening · 2 holdingNext resultsFeb 11, 2027Projected from its filing dates

AMWL at a glance

The past year

Chart

+178.7% $11.04, close Nov 18

From the highest close
−26.3%
Vs the 200-day average
+17.4%
Nov 17, 2025Daily close, American WellNov 18, 2026

Short interest

History

250,235 shares

Of shares outstanding
1.61%
Since the last report
+21.1%
Days to cover
1.7 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 13 – Nov 19

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

AMWL price history

Latest price$11.03Today−$0.17 (-1.52%)
AMWL -8.16%S&P 500 -5.00%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • Healthcare buyers continue to value a dedicated, regulated digital-care platform over generic video tools or bundled EHR offerings, allowing AMWL to defend its installed base rather than becoming a commoditized feature.HoldingMateriality: High

    Annual GAAP revenue remained material at $249.3 million in FY2025 despite heavy competitive pressure disclosed in MD&A. If this holds, revenue can stabilize and the turnaround has time; if it breaks, cost cuts cannot offset structural demand loss.

    Watch: Epic, Cerner, Allscripts, or athenahealth make virtual-care workflows sufficiently native to the EHR that clients stop buying a separate AMWL platform.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Annual GAAP revenue remained material at $249.3 million in FY2025 despite heavy competitive pressure disclosed in MD&A.

    Open source ↗
  • Management’s cost actions and platform focus are improving operating leverage without cutting so deeply that the product becomes uncompetitive.StrengtheningMateriality: High

    Annual GAAP operating loss improved from $217.5 million in FY2024 to $105.3 million in FY2025. This determines whether AMWL can become self-funding or must rely on its balance sheet and possible dilution.

    Watch: Competitor product advances force AMWL to reaccelerate R&D and sales spending before revenue improves.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Annual GAAP operating loss improved from $217.5 million in FY2024 to $105.3 million in FY2025.

    Open source ↗
  • AMWL’s cash balance gives it enough runway to execute the turnaround, but only if cash burn keeps moving down rather than reaccelerating.StrengtheningMateriality: Medium

    Cash was $182.3 million at FY2025 year-end. If runway holds, shareholders retain turnaround optionality; if burn reaccelerates, dilution or strategic distress becomes central.

    Watch: Regulatory compliance costs rise materially because AMWL must restructure clinical or AMG-related arrangements.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $182.3 million at FY2025 year-end.

    Open source ↗
  • Healthcare regulatory complexity remains a barrier that favors specialized digital-care operators, rather than becoming a compliance shock that forces AMWL to alter services or restructure clinical relationships at high cost.HoldingMateriality: Medium

    The company’s filing identifies corporate practice of medicine, licensure, online prescribing, privacy, cybersecurity, Stark Law, and Anti-Kickback Statute compliance as central operating requirements. If compliance know-how is an advantage, it helps defend pricing and customer trust; if regulators force changes, revenue and margins can deteriorate quickly.

    Watch: Federal or state regulators scrutinize AMWL’s AMG relationship or corporate-practice-of-medicine structure and require costly restructuring.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    The company’s filing identifies corporate practice of medicine, licensure, online prescribing, privacy, cybersecurity, Stark Law, and Anti-Kickback Statute compliance as.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Healthcare buyers continue to value a dedicated, regulated digital-care platform over generic video tools or bundled EHR offerings, allowing AMWL to defend its installed base rather than becoming a commoditized feature. If this holds, revenue can stabilize and the turnaround has time; if it breaks, cost cuts cannot offset structural demand loss.

Management’s cost actions and platform focus are improving operating leverage without cutting so deeply that the product becomes uncompetitive. This determines whether AMWL can become self-funding or must rely on its balance sheet and possible dilution.

AMWL’s cash balance gives it enough runway to execute the turnaround, but only if cash burn keeps moving down rather than reaccelerating. If runway holds, shareholders retain turnaround optionality; if burn reaccelerates, dilution or strategic distress becomes central.

Healthcare regulatory complexity remains a barrier that favors specialized digital-care operators, rather than becoming a compliance shock that forces AMWL to alter services or restructure clinical relationships at high cost. If compliance know-how is an advantage, it helps defend pricing and customer trust; if regulators force changes, revenue and margins can deteriorate quickly.

All standing thesis claims
Original report summary

large healthcare buyers keep paying for a dedicated digital-care platform while management turns a still-lossmaking revenue base into self-funding cash flow.

Evidence assessed Oct 17, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for American Well

Where the evidence on American Well stands: Holding on the latest evidence (Oct 17, 2026). Of its 4 thesis points, 2 strengthening and 2 holding.

Bull case: what the evidence supports

  • Healthcare buyers continue to value a dedicated, regulated digital-care platform over generic video tools or bundled EHR offerings, allowing AMWL to defend its installed base rather than becoming a commoditized feature.

    sec.gov ↗

  • Management’s cost actions and platform focus are improving operating leverage without cutting so deeply that the product becomes uncompetitive.

    sec.gov ↗

  • AMWL’s cash balance gives it enough runway to execute the turnaround, but only if cash burn keeps moving down rather than reaccelerating.

    sec.gov ↗

  • Healthcare regulatory complexity remains a barrier that favors specialized digital-care operators, rather than becoming a compliance shock that forces AMWL to alter services or restructure clinical relationships at high cost.

    sec.gov ↗

Bear case: what would count against it

  • Epic, Cerner, Allscripts, or athenahealth make virtual-care workflows sufficiently native to the EHR that clients stop buying a separate AMWL platform.

    sec.gov ↗

  • Competitor product advances force AMWL to reaccelerate R&D and sales spending before revenue improves.

    sec.gov ↗

  • Regulatory compliance costs rise materially because AMWL must restructure clinical or AMG-related arrangements.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · American Well

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed American Well’s thesis. Its break conditions are checked against every new filing as it lands.

Early warning

The break condition read on the trailing twelve months through American Well’s latest quarterly report, ahead of the annual figure it is written on.

  • Revenue decline, trailing 12 months

    Across all companies, this kind of early warning has happened 3,039 times before. Those stocks beat the market by a median of 1% over the next six months, and 32% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    American Well filed an SEC 8-K on 2026-08-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Changed certifying accountant.

    American Well filed an SEC 8-K on 2026-07-21: Changed certifying accountant. It is a dated development that tests the current thesis.

  3. Mixed
    Director or principal officer change.

    American Well filed an SEC 8-K on 2026-07-14: Director or principal officer change. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Epic, Cerner, Allscripts, or athenahealth make virtual-care workflows sufficiently native to the EHR that clients stop buying a separate AMWL platform.
  • Competitor product advances force AMWL to reaccelerate R&D and sales spending before revenue improves.
  • Regulatory compliance costs rise materially because AMWL must restructure clinical or AMG-related arrangements.
  • Federal or state regulators scrutinize AMWL’s AMG relationship or corporate-practice-of-medicine structure and require costly restructuring.

AMWL news

Loading headlines…

Financial statements

AMWL income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

AMWL: quick answers

When does American Well (AMWL) report earnings next?
American Well's next results are projected for February 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 3, 2026. Earnings calendar
What is AMWL's short interest?
As of October 30, 2026, 250,235 AMWL shares were sold short, 1.61% of its shares outstanding, up 21.1% from the count before. At the stock's average daily volume that is 1.7 days to cover. FINRA publishes the count twice a month. AMWL short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.